Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish Sells 27,453 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 27,453 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the sale, the chief operating officer now owns 867,677 shares in the company, valued at $9,969,608.73. This represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Alphatec Trading Down 0.5 %

Alphatec stock opened at $11.36 on Friday. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $17.34. The stock has a market cap of $1.61 billion, a P/E ratio of -8.88 and a beta of 1.43. The firm’s fifty day moving average price is $10.26 and its 200-day moving average price is $8.13.

Hedge Funds Weigh In On Alphatec

A number of institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company increased its position in shares of Alphatec by 8.9% in the second quarter. The Manufacturers Life Insurance Company now owns 58,257 shares of the medical technology company’s stock worth $609,000 after purchasing an additional 4,755 shares during the last quarter. Creative Planning grew its stake in Alphatec by 112.7% in the 2nd quarter. Creative Planning now owns 26,440 shares of the medical technology company’s stock worth $276,000 after buying an additional 14,007 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Alphatec by 207.7% in the 3rd quarter. SG Americas Securities LLC now owns 44,603 shares of the medical technology company’s stock worth $248,000 after buying an additional 30,108 shares during the last quarter. Procyon Advisors LLC raised its position in shares of Alphatec by 94.5% during the 3rd quarter. Procyon Advisors LLC now owns 57,930 shares of the medical technology company’s stock valued at $322,000 after buying an additional 28,150 shares in the last quarter. Finally, Net Worth Advisory Group purchased a new stake in shares of Alphatec during the 3rd quarter valued at $76,000. 66.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on ATEC shares. Needham & Company LLC boosted their price target on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Finally, Barclays increased their target price on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Alphatec currently has an average rating of “Moderate Buy” and an average price target of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.